- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07575113
Comparison of Otago and Beat it Program on Balance, Gait and QOL in Diabetic Neuropathy
Comparative Effects of Otago Exercise Program and Beat it Program on Balance, Gait and Quality of Life in Patients With Diabetic Peripheral Neuropathy
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Muneeb Khan, PhD
- Telefonnummer: +92336799611
- E-post: muneeb.khan@riphah.edu.pk
Studiesteder
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan, 54500
- THQ hospital
-
Ta kontakt med:
- Javeria Ghazal, MS
- Telefonnummer: +923335154664
- E-post: javeria.ghazal@riphah.edu.pk
-
Hovedetterforsker:
- Sania Hassan, MS
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- physician-diagnosed type 2 diabetes, with peripheral neuropathy (defined by Michigan Neuropathy Screening Instrument questionnaire score of 5 or greater) the ability to walk independently for 20 m (97).
- Having score between 46 to 52 (out of a total of 56 points) on the BBS
Exclusion Criteria:
- fracture of the lower limb within the 6 months before the study
- diabetic ulcer, infection or partial amputation in feet
- disease or functional impairment of auditory, vestibular system
- Dementia or inability to give consistent information
- History of surgical procedure at the knee, ankle, or hip or indication of surgery throughout the intervention period malignancy, other neurological or orthopedic impairments (such as stroke, poliomyelitis, rheumatoid arthritis, prosthesis, or severe osteoarthritis), major vascular complications (venous or arterial ulcers), severe retinopathy, or severe nephropathy that causes edema or needs hemodialysis
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Otago program
Participants performed a combination of warm-up, strengthening, balance, and aerobic exercises at home.
|
The program included: 5 Strengthening exercises and 12 balance exercises. 30-40 min, 4x/week for 8 weeks. Balance Exercises: Knee bends Backwards walking Walking and turning around Sideways walking Tandem stance (heel toe stance) Tandem walk (heel toe walk) One leg stance Heel walking Toe walk Heel toe walking backwards Sit to stand Stair walking Strength exercises: Knee extensor Knee flexor Hip adductor Ankle planter flexors (calf raises) Ankle dorsiflexors (toe raises) |
|
Eksperimentell: BEAT it program
Participants performed moderate-intensity aerobic, resistance, balance, and flexibility exercises, along with education on diabetes self-management.
The exercises were designed to be completed at home using minimal equipment or household items
|
Strengthening exercises Toe spreading Ankle pump Mini wall squats Slow march in standing Knee with pillow press up Bridging Step up and down on stair 1st step Toe curls Stretching Hamstring stretch Dorsiflexors and planter flexors stretch Quads stretch Biceps stretch Triceps stretch Balance exercises Leg front and back swinging Weight shifting front and back Leg sideways Sideway alternate step Tandem stand Alternate heel toe raises Sessions were performed;
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
4 Stage Balance Test
Tidsramme: 8th week
|
The Four Stage Balance Test is a validated measure recommended to evaluate static balance. Four standing positions get progressively harder to maintain.
|
8th week
|
|
Mini BESTest
Tidsramme: 8th week
|
This test measures dynamic balance, functional mobility, and gait.
The Mini-BESTest, the shortened form of BESTest, contains only 14 different tasks and involves four sub-sections: anticipatory postural adjustments, postural response to external perturbations, sensory orientation, and stability in gait.
Two items of Mini-BESTest are assessed bilaterally, but only the lower score was added to the maximum score of 28 points, which results from grading based on a 3-point ordinal scale ranging from 0 (severe balance impairment) to 2 (no balance impairment) (108).
Reliability 0.98; Validity 0.65.
|
8th week
|
|
Functional Reach Test
Tidsramme: 8th week
|
FRT is used to evaluate anticipatory balance which correlates with fall risks.
This test measures the margin of stability along with the ability to measure balance during a functional task.
Reliability 0.89; Sensitivity 76%; Specificity 34%
|
8th week
|
|
Functional Gait Assessment
Tidsramme: 8th week
|
The FGA has been validated for the assessment of balance in people with vestibular dysfunction, community-dwelling older adults, patients with stroke, and patients with Parkinson disease.
The FGA has good reliability (interrater reliability: intraclass correlation coefficient [ICC]=.74;
interrater reliability: ICC=.86 to .93) and internal consistency (Cronbach alpha=.79)
|
8th week
|
|
Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire
Tidsramme: 8th week
|
The Norfolk Quality-of Life Diabetic Neuropathy tool (QOL-DN) has been found to be reliable across many different populations.
This comprehensive tool has demonstrated sensitivity to both small and large fiber impairment while also detecting improvements in neuropathy.
Intra class Reliability >0.9; Internal Consistency >0.6
|
8th week
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Javeria Ghazal, MS, Riphah International University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- REC/RCR &AHS/24/0296
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .